Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.

ABSTRACT:

Background

The repeated waves of the COVID-19 pandemic have highlighted the necessity to optimize vaccine responses in immunocompromised populations. We investigated the safety and immunogenicity of a third, booster, dose of the Pfizer BNT162b2 vaccine in heart transplant (HT) patients.

Methods

The cohort comprised 96 adult HT patients who received a third homologous dose of the BNT162b2 vaccine 168 days after the second dose. The vaccine-induced antibody responses of both receptor-binding domain (RBD) IgG and neutralizing antibodies were assessed in all patients, with a positive antibody response being defined as the presence of either IgG anti-RBD or neutralizing antibodies. For a subset of patients, T cell response was also studied.

Results

The third dose was assoc

SUBMITTER: Peled Y 

PROVIDER: S-EPMC8397500 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature